0808 GMT - DSM-Firmenich will likely communicate on capital returns in advance of further divestment, Jefferies analysts write in a note. The sale of its stake in the Feed Enzymes Alliance to its partner Novonesis brings focus to its balance sheet, the analysts say. "The combination of this divestment and the previously announced Robertet sale represents around 1.8 billion euros of net proceeds from divestment," they add. This suggests that the Dutch nutrition, health and bioscience company could communicate on capital returns even before the finalized remaining Animal Nutrition and Health sale. Shares closed Monday at 95.94 euros. (najat.kantouar@wsj.com)
(END) Dow Jones Newswires
February 11, 2025 03:08 ET (08:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。